Displaying 97 - 108 of 492
Metabolism, Alcohol & Toxicity

Takeda: "Alpha-1 antitrypsin deficiency (AATD) - Associated liver disease: More common than you may think" (Complete Session)

Webcasts
View
Immune-Mediated and Cholestatic Diseases

Albireo Pharma, an Ipsen Company: “New Horizons in cholestatic liver disease” (Complete Session)

Webcasts
View
Immune-Mediated and Cholestatic Diseases

Ipsen: "Scratching beyond the surface in PBC: From current unmet medical needs to future prospects" (Complete Session)

Webcasts
View
Metabolism, Alcohol & Toxicity

Madrigal Pharmaceuticals: "Emerging role of the hepatic thyroid pathway in the pathophysiology of NASH" (Complete Session)

Webcasts
View
Immune-Mediated and Cholestatic Diseases

Mirum Pharmaceuticals, Inc: "Meet the Experts in Cholestatic Liver Disease" (Complete Session)

Webcasts
View
Metabolism, Alcohol & Toxicity

Novo Nordisk and Echosens: "Clinical challenge: Updates on the non-invasive toolbox for NASH and Fibrosis" (Complete Session)

Webcasts
View
Metabolism, Alcohol & Toxicity

Discussion and Q&A

Webcasts
View
Metabolism, Alcohol & Toxicity

Introduction

Webcasts
View
Metabolism, Alcohol & Toxicity

NASH: a growing unmet therapeutic need

Webcasts
View
Metabolism, Alcohol & Toxicity

The underestimated role of thyroid hormone pathway in the pathophysiology of NASH

Webcasts
View
Metabolism, Alcohol & Toxicity

Key take home messages and close

Webcasts
View
Metabolism, Alcohol & Toxicity

Welcome and introduction

Webcasts
View
Displaying 97 - 108 of 492